Menu
The Goodman Institute Health Blog
  • Home
  • Authors
    • Devon Herrick, Ph.D.
    • John C. Goodman
  • Popular Topics
    • Artificial Intelligence and Healthcare
    • Consumer-Driven Health Care
      • Affordable Care Act
      • Cost of Healthcare
      • COVID-19 and Public Health
      • Doctors & Hospitals
      • Public Insurance
      • Policy & Legislation
    • Direct Primary Care
    • Health Economics & Costs
      • Drug Prices & Regulations
      • Health Insurance
      • Health Reform
    • Medical Tourism
    • Telemedicine
    • Medicare
      • Single-Payer/Medicare-for-All
  • Goodman Institute
  • Contact
The Goodman Institute Health Blog

Category: Devon Herrick

Would You Discuss Your Health with an AI Chatbot?

Posted on November 3, 2025 by Devon Herrick

From the Wall Street Journal, Daniel Akst wrote:

Once upon a time, my wife’s uncle, Jim, delivered babies, set broken bones, diagnosed diseases, and helped people reconcile themselves to mortality. That’s what family physicians did in those days.
Things are different now, and the doctor I most often consult is AI. I’d prefer to see Uncle Jim, but if physicians like him still exist somewhere, I doubt I could get an appointment. How I ended up resorting to artificial intelligence—despite excellent health insurance and proximity to great care—says a lot about the state of healthcare in this country.

+

Why is Health Reform So Difficult?

Posted on October 31, 2025 by Devon Herrick

Why can’t people agree on strategies to fix health care? It is due to many things, including disagreements on health economics, self-interest, and fundamental differences in ideology. Every public intellectual has an idea that may, or may not, do anything to improve health care.

+

Should Drugmakers Have to Prove Their Drugs Work?

Posted on October 29, 2025 by Devon Herrick

New drugs benefit American patients. Increasing the number of drugs in the pipeline will likely boost drug spending but also increase the number of new or improved drug therapies. It will also increase the number of generic drugs 20 years down the road. Shortening the length of time it takes new drugs to gain approval would also boost competition with earlier drugs that are still under patent protection. 

+

The Cost of Pet Cancer Care Rivals a Car, Yet Texas Limits Competition

Posted on October 27, 2025 by Devon Herrick

This topic became an issue for me because of my dog Clementine. I recently wrote about her experience at the veterinarian. She had surgery for bladder stones, but the surgery did not resolve her problems. We took her back twice more, finally getting a referral to a specialist. A veterinary internal medicine specialist did a very thorough examination costing nearly $1,500. The pathology report found cancer that had metastasized.

+
  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 192
  • Next

For many years, our health care blog was the only free enterprise health policy blog on the internet. Then, when the NCPA closed its doors, the health blog stopped as well.

During this five-year hiatus no one else has come forward to claim the space. So, my colleagues and I have decided to restart the blog in connection with the Goodman Institute. We invite you and others to use this forum to share your views.

John C. Goodman,

Visit www.goodmaninstitute.org

Subscribe via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 40 other subscribers

Popular Topics

©2025 The Goodman Institute Health Blog | Website by Lexicom